耶氏肺孢子菌肺炎预防对原发性脑肿瘤放化疗患者血液学毒性的影响
回顾性分析217例接受放疗联合替莫唑胺的原发性脑肿瘤患者,比较甲氧苄啶-磺胺甲噁唑(TMP/SMX)与喷他脒预防耶氏肺孢子菌肺炎(PJP)时血液学毒性差异。TMP/SMX组中性粒细胞绝对值<1500 cells/µL发生率为15.3%,喷他脒组为7.2%(p=0.10);血小板<100,000/µL发生率分别为18.1%与20.3%(p=0.70);淋巴细胞计数无显著差异,毒性严重程度相似。作者认为PJP预防药物类型未显著影响血液学毒性风险。
要点
- TMP/SMX组中性粒细胞<1500 cells/µL发生率15.3%,喷他脒组7.2%(p=0.10)。
- TMP/SMX组血小板<100,000/µL发生率18.1%,喷他脒组20.3%(p=0.70)。
- 两种预防方案间淋巴细胞计数无显著差异,血液学毒性严重程度相似。
核心结论
- 作者认为PJP预防药物类型未显著影响接受放疗联合替莫唑胺的脑肿瘤患者发生血液学毒性的风险,并认为TMP/SMX组观察到的较高中性粒细胞减少率值得进一步研究。
研究设计与样本
- 回顾性病历审查,纳入217例接受放疗联合替莫唑胺治疗的原发性脑肿瘤患者,其中144例接受TMP/SMX预防,69例接受喷他脒预防。
主要发现
- TMP/SMX组中性粒细胞绝对值<1500 cells/µL发生率为15.3%,喷他脒组为7.2%(p=0.10)。
- TMP/SMX组血小板计数<100,000/µL发生率为18.1%,喷他脒组为20.3%(p=0.70)。
- 两种预防方案间淋巴细胞计数无显著差异,血液学毒性严重程度相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diffuse gliomas are managed with radiation and temozolomide; however, this therapy often results in hematologic toxicities. Patients undergoing chemoradiation also risk contracting Pneumocystis jirovecii pneumonia (PJP), and frequently receive prophylaxis against PJP during treatment. Independent of chemoradiation, some PJP prophylaxis drugs have the potential to cause myelosuppression, which could require cessation of chemotherapy. Here, we evaluate differences in the frequency of hematologic toxicities during chemoradiation when patients receive PJP prophylaxis. METHODS: This retrospective chart review evaluated patients with primary brain tumors treated with radiation and concurrent temozolomide. Analyses were performed to assess the effect of the type of PJP prophylaxis on risk for neutropenia, lymphopenia, or thrombocytopenia and the severity of these adverse effects as defined using the Common Terminology Criteria for Adverse Events. RESULTS: Of the 217 patients included in this analysis, 144 received trimethoprim-sulfamethoxazole (TMP/SMX) and 69 received pentamidine. Of the patients who received TMP/SMX, 15.3% developed an absolute neutrophil count < 1500 cells/µL compared with 7.2% of patients receiving pentamidine (p = 0.10). Platelet count < 100,000/µL occurred in 18.1% of patients who received TMP/SMX and 20.3% of patients who received pentamidine (p = 0.70). No significant differences in lymphocyte counts between therapies were seen. Severity of hematologic toxicities were similar between PJP prophylaxis groups. CONCLUSION: These findings suggest that the type of PJP prophylaxis does not significantly affect the risk for hematologic toxicity in brain tumor patients receiving radiation and temozolomide. Additional studies are merited to evaluate the higher rate of neutropenia in patients on TMP/SMX observed in this study.
引用
- Arnold LM, Hoshina Y, Lee H, et al. Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors. J Neurooncol. 2024. PMID: 38363493. doi:10.1007/s11060-024-04588-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。